Japan Society of Gynecologic Oncology guidelines 2017 for the treatment of uterine cervical cancer

Yasuhiko Ebina, Mikio Mikami, Satoru Nagase, Tsutomu Tabata, Masanori Kaneuchi, Hironori Tashiro, Masaki Mandai, Takayuki Enomoto, Yoichi Kobayashi, Hidetaka Katabuchi, Nobuo Yaegashi, Yasuhiro Udagawa, Daisuke Aoki

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The Japan Society of Gynecologic Oncology (JSGO) Guidelines 2017 for the Treatment of Uterine Cervical Cancer are for the purpose of providing standard treatment strategies for cervical cancer, indicating treatment methods currently considered appropriate for cervical cancer, minimizing variances in treatment methods among institutions, improving the safety of treatment and prognosis of diseases, reducing the economic and psychosomatic burden of patients by promoting performance of appropriate treatment, and enhancing mutual understanding between patients and healthcare professionals. The guidelines were prepared through consensus of the JSGO Guideline Committee, based on careful review of evidence gathered through the literature searches and in view of the medical health insurance system and actual clinical practice situations in Japan. The guidelines comprise eight chapters and five algorithms. The main features of the 2017 revision are as follows: (1) evidence was collected using a search formula and with cooperation of the Japan Library Association. The bibliographical search formula was placed at the end of the book; (2) regarding clinical questions (CQs) where evidence or clinical inspection in Japan was lacking, opinions of the Guidelines Committee were described as “proposals for future directions”; (3) cervical intraepithelial neoplasia (CIN) 3 and adenocarcinoma in situ (AIS) were treated as a cervical precancerous lesion; (4) the CQs of endoscopic surgery, radical trachelectomy, and sentinel node biopsy were newly added in Chapter 3, “primary treatment for stage IB–II cervical cancer”; and (5) the CQ about hormone replacement therapy after cancer treatment was newly established. Each recommendation is accompanied by a classification of recommendation categories based on the consensus reached by the Guideline Committee members. Here, we present the English version of the JSGO Guidelines 2017 for the Treatment of Uterine Cervical Cancer.

Original languageEnglish
JournalInternational Journal of Clinical Oncology
DOIs
Publication statusAccepted/In press - 2018 Jan 1

Fingerprint

Uterine Cervical Neoplasms
Japan
Guidelines
Therapeutics
Library Associations
Committee Membership
Cervical Intraepithelial Neoplasia
Hormone Replacement Therapy
Health Insurance
Economics
Delivery of Health Care
Biopsy
Safety

Keywords

  • Chemotherapy
  • Clinical practice guidelines
  • Irradiation
  • Recurrence
  • Surgery
  • Uterine cervical cancer

ASJC Scopus subject areas

  • Surgery
  • Hematology
  • Oncology

Cite this

Japan Society of Gynecologic Oncology guidelines 2017 for the treatment of uterine cervical cancer. / Ebina, Yasuhiko; Mikami, Mikio; Nagase, Satoru; Tabata, Tsutomu; Kaneuchi, Masanori; Tashiro, Hironori; Mandai, Masaki; Enomoto, Takayuki; Kobayashi, Yoichi; Katabuchi, Hidetaka; Yaegashi, Nobuo; Udagawa, Yasuhiro; Aoki, Daisuke.

In: International Journal of Clinical Oncology, 01.01.2018.

Research output: Contribution to journalArticle

Ebina, Y, Mikami, M, Nagase, S, Tabata, T, Kaneuchi, M, Tashiro, H, Mandai, M, Enomoto, T, Kobayashi, Y, Katabuchi, H, Yaegashi, N, Udagawa, Y & Aoki, D 2018, 'Japan Society of Gynecologic Oncology guidelines 2017 for the treatment of uterine cervical cancer', International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-018-1351-y
Ebina, Yasuhiko ; Mikami, Mikio ; Nagase, Satoru ; Tabata, Tsutomu ; Kaneuchi, Masanori ; Tashiro, Hironori ; Mandai, Masaki ; Enomoto, Takayuki ; Kobayashi, Yoichi ; Katabuchi, Hidetaka ; Yaegashi, Nobuo ; Udagawa, Yasuhiro ; Aoki, Daisuke. / Japan Society of Gynecologic Oncology guidelines 2017 for the treatment of uterine cervical cancer. In: International Journal of Clinical Oncology. 2018.
@article{fa8991a8ab2f408da9199f4dbf4a83d3,
title = "Japan Society of Gynecologic Oncology guidelines 2017 for the treatment of uterine cervical cancer",
abstract = "The Japan Society of Gynecologic Oncology (JSGO) Guidelines 2017 for the Treatment of Uterine Cervical Cancer are for the purpose of providing standard treatment strategies for cervical cancer, indicating treatment methods currently considered appropriate for cervical cancer, minimizing variances in treatment methods among institutions, improving the safety of treatment and prognosis of diseases, reducing the economic and psychosomatic burden of patients by promoting performance of appropriate treatment, and enhancing mutual understanding between patients and healthcare professionals. The guidelines were prepared through consensus of the JSGO Guideline Committee, based on careful review of evidence gathered through the literature searches and in view of the medical health insurance system and actual clinical practice situations in Japan. The guidelines comprise eight chapters and five algorithms. The main features of the 2017 revision are as follows: (1) evidence was collected using a search formula and with cooperation of the Japan Library Association. The bibliographical search formula was placed at the end of the book; (2) regarding clinical questions (CQs) where evidence or clinical inspection in Japan was lacking, opinions of the Guidelines Committee were described as “proposals for future directions”; (3) cervical intraepithelial neoplasia (CIN) 3 and adenocarcinoma in situ (AIS) were treated as a cervical precancerous lesion; (4) the CQs of endoscopic surgery, radical trachelectomy, and sentinel node biopsy were newly added in Chapter 3, “primary treatment for stage IB–II cervical cancer”; and (5) the CQ about hormone replacement therapy after cancer treatment was newly established. Each recommendation is accompanied by a classification of recommendation categories based on the consensus reached by the Guideline Committee members. Here, we present the English version of the JSGO Guidelines 2017 for the Treatment of Uterine Cervical Cancer.",
keywords = "Chemotherapy, Clinical practice guidelines, Irradiation, Recurrence, Surgery, Uterine cervical cancer",
author = "Yasuhiko Ebina and Mikio Mikami and Satoru Nagase and Tsutomu Tabata and Masanori Kaneuchi and Hironori Tashiro and Masaki Mandai and Takayuki Enomoto and Yoichi Kobayashi and Hidetaka Katabuchi and Nobuo Yaegashi and Yasuhiro Udagawa and Daisuke Aoki",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/s10147-018-1351-y",
language = "English",
journal = "International Journal of Clinical Oncology",
issn = "1341-9625",
publisher = "Springer Japan",

}

TY - JOUR

T1 - Japan Society of Gynecologic Oncology guidelines 2017 for the treatment of uterine cervical cancer

AU - Ebina, Yasuhiko

AU - Mikami, Mikio

AU - Nagase, Satoru

AU - Tabata, Tsutomu

AU - Kaneuchi, Masanori

AU - Tashiro, Hironori

AU - Mandai, Masaki

AU - Enomoto, Takayuki

AU - Kobayashi, Yoichi

AU - Katabuchi, Hidetaka

AU - Yaegashi, Nobuo

AU - Udagawa, Yasuhiro

AU - Aoki, Daisuke

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The Japan Society of Gynecologic Oncology (JSGO) Guidelines 2017 for the Treatment of Uterine Cervical Cancer are for the purpose of providing standard treatment strategies for cervical cancer, indicating treatment methods currently considered appropriate for cervical cancer, minimizing variances in treatment methods among institutions, improving the safety of treatment and prognosis of diseases, reducing the economic and psychosomatic burden of patients by promoting performance of appropriate treatment, and enhancing mutual understanding between patients and healthcare professionals. The guidelines were prepared through consensus of the JSGO Guideline Committee, based on careful review of evidence gathered through the literature searches and in view of the medical health insurance system and actual clinical practice situations in Japan. The guidelines comprise eight chapters and five algorithms. The main features of the 2017 revision are as follows: (1) evidence was collected using a search formula and with cooperation of the Japan Library Association. The bibliographical search formula was placed at the end of the book; (2) regarding clinical questions (CQs) where evidence or clinical inspection in Japan was lacking, opinions of the Guidelines Committee were described as “proposals for future directions”; (3) cervical intraepithelial neoplasia (CIN) 3 and adenocarcinoma in situ (AIS) were treated as a cervical precancerous lesion; (4) the CQs of endoscopic surgery, radical trachelectomy, and sentinel node biopsy were newly added in Chapter 3, “primary treatment for stage IB–II cervical cancer”; and (5) the CQ about hormone replacement therapy after cancer treatment was newly established. Each recommendation is accompanied by a classification of recommendation categories based on the consensus reached by the Guideline Committee members. Here, we present the English version of the JSGO Guidelines 2017 for the Treatment of Uterine Cervical Cancer.

AB - The Japan Society of Gynecologic Oncology (JSGO) Guidelines 2017 for the Treatment of Uterine Cervical Cancer are for the purpose of providing standard treatment strategies for cervical cancer, indicating treatment methods currently considered appropriate for cervical cancer, minimizing variances in treatment methods among institutions, improving the safety of treatment and prognosis of diseases, reducing the economic and psychosomatic burden of patients by promoting performance of appropriate treatment, and enhancing mutual understanding between patients and healthcare professionals. The guidelines were prepared through consensus of the JSGO Guideline Committee, based on careful review of evidence gathered through the literature searches and in view of the medical health insurance system and actual clinical practice situations in Japan. The guidelines comprise eight chapters and five algorithms. The main features of the 2017 revision are as follows: (1) evidence was collected using a search formula and with cooperation of the Japan Library Association. The bibliographical search formula was placed at the end of the book; (2) regarding clinical questions (CQs) where evidence or clinical inspection in Japan was lacking, opinions of the Guidelines Committee were described as “proposals for future directions”; (3) cervical intraepithelial neoplasia (CIN) 3 and adenocarcinoma in situ (AIS) were treated as a cervical precancerous lesion; (4) the CQs of endoscopic surgery, radical trachelectomy, and sentinel node biopsy were newly added in Chapter 3, “primary treatment for stage IB–II cervical cancer”; and (5) the CQ about hormone replacement therapy after cancer treatment was newly established. Each recommendation is accompanied by a classification of recommendation categories based on the consensus reached by the Guideline Committee members. Here, we present the English version of the JSGO Guidelines 2017 for the Treatment of Uterine Cervical Cancer.

KW - Chemotherapy

KW - Clinical practice guidelines

KW - Irradiation

KW - Recurrence

KW - Surgery

KW - Uterine cervical cancer

UR - http://www.scopus.com/inward/record.url?scp=85054692942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054692942&partnerID=8YFLogxK

U2 - 10.1007/s10147-018-1351-y

DO - 10.1007/s10147-018-1351-y

M3 - Article

JO - International Journal of Clinical Oncology

JF - International Journal of Clinical Oncology

SN - 1341-9625

ER -